163 related articles for article (PubMed ID: 30535501)
21. MicroRNA‑223‑induced inhibition of the
Liu Z; Ma T; Duan J; Liu X; Liu L
Mol Med Rep; 2021 Feb; 23(2):. PubMed ID: 33355365
[TBL] [Abstract][Full Text] [Related]
22. The BAFF/NFκB axis is crucial to interactions between sorafenib-resistant HCC cells and cancer-associated fibroblasts.
Gao L; Morine Y; Yamada S; Saito Y; Ikemoto T; Tokuda K; Miyazaki K; Okikawa S; Takasu C; Shimada M
Cancer Sci; 2021 Sep; 112(9):3545-3554. PubMed ID: 34159680
[TBL] [Abstract][Full Text] [Related]
23. LncRNA AC026401.3 interacts with OCT1 to intensify sorafenib and lenvatinib resistance by activating E2F2 signaling in hepatocellular carcinoma.
Wang Y; Tan K; Hu W; Hou Y; Yang G
Exp Cell Res; 2022 Nov; 420(1):113335. PubMed ID: 36084669
[TBL] [Abstract][Full Text] [Related]
24. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
25. An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells.
Tang S; Tan G; Jiang X; Han P; Zhai B; Dong X; Qiao H; Jiang H; Sun X
Oncotarget; 2016 Nov; 7(45):73257-73269. PubMed ID: 27689326
[TBL] [Abstract][Full Text] [Related]
26. The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma.
Pollutri D; Patrizi C; Marinelli S; Giovannini C; Trombetta E; Giannone FA; Baldassarre M; Quarta S; Vandewynckel YP; Vandierendonck A; Van Vlierberghe H; Porretti L; Negrini M; Bolondi L; Gramantieri L; Fornari F
Cell Death Dis; 2018 Jan; 9(1):4. PubMed ID: 29305580
[TBL] [Abstract][Full Text] [Related]
27. EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC.
Yin Y; Sun M; Zhan X; Wu C; Geng P; Sun X; Wu Y; Zhang S; Qin J; Zhuang Z; Liu Y
J Exp Clin Cancer Res; 2019 Feb; 38(1):83. PubMed ID: 30770740
[TBL] [Abstract][Full Text] [Related]
28. ETS-1 induces Sorafenib-resistance in hepatocellular carcinoma cells via regulating transcription factor activity of PXR.
Shao Z; Li Y; Dai W; Jia H; Zhang Y; Jiang Q; Chai Y; Li X; Sun H; Yang R; Cao Y; Feng F; Guo Y
Pharmacol Res; 2018 Sep; 135():188-200. PubMed ID: 30114438
[TBL] [Abstract][Full Text] [Related]
29. Long Noncoding RNA (lncRNA) Small Nucleolar RNA Host Gene 16 (SNHG16) Predicts Poor Prognosis and Sorafenib Resistance in Hepatocellular Carcinoma.
Guo Z; Zhang J; Fan L; Liu J; Yu H; Li X; Sun G
Med Sci Monit; 2019 Mar; 25():2079-2086. PubMed ID: 30893293
[TBL] [Abstract][Full Text] [Related]
30. TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma.
Lai HH; Li CW; Hong CC; Sun HY; Chiu CF; Ou DL; Chen PS
Mol Oncol; 2019 Apr; 13(4):928-945. PubMed ID: 30657254
[TBL] [Abstract][Full Text] [Related]
31. Sestrin 2 confers primary resistance to sorafenib by simultaneously activating AKT and AMPK in hepatocellular carcinoma.
Dai J; Huang Q; Niu K; Wang B; Li Y; Dai C; Chen Z; Tao K; Dai J
Cancer Med; 2018 Nov; 7(11):5691-5703. PubMed ID: 30311444
[TBL] [Abstract][Full Text] [Related]
32. PERK/ATF4-Dependent ZFAS1 Upregulation Is Associated with Sorafenib Resistance in Hepatocellular Carcinoma Cells.
Lin JC; Yang PM; Liu TP
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072570
[TBL] [Abstract][Full Text] [Related]
33. Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Is a Novel Prognostic Marker and Contributes to Sorafenib Resistance in Hepatocellular Carcinoma.
Dietrich P; Gaza A; Wormser L; Fritz V; Hellerbrand C; Bosserhoff AK
Neoplasia; 2019 Mar; 21(3):257-268. PubMed ID: 30685691
[TBL] [Abstract][Full Text] [Related]
34. YAP promotes sorafenib resistance in hepatocellular carcinoma by upregulating survivin.
Sun T; Mao W; Peng H; Wang Q; Jiao L
Cell Oncol (Dordr); 2021 Jun; 44(3):689-699. PubMed ID: 33655469
[TBL] [Abstract][Full Text] [Related]
35. MiR-128-3p overexpression sensitizes hepatocellular carcinoma cells to sorafenib induced apoptosis through regulating DJ-1.
Guo XL; Wang HB; Yong JK; Zhong J; Li QH
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(20):6667-6677. PubMed ID: 30402839
[TBL] [Abstract][Full Text] [Related]
36. Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines.
Kim JS; Choi GH; Jung Y; Kim KM; Jang SJ; Yu ES; Lee HC
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1487-1501. PubMed ID: 29858683
[TBL] [Abstract][Full Text] [Related]
37. FOXM1 augments sorafenib resistance and promotes progression of hepatocellular carcinoma by epigenetically activating KIF23 expression.
Zhu C; Guo H; Ma Z; Shi S; Zhao X; Zhai D; Zhou X; Jiang P; Xu Q; Cai J
Biochem Biophys Res Commun; 2023 May; 656():1-9. PubMed ID: 36940637
[TBL] [Abstract][Full Text] [Related]
38. Up-regulation of miR-877 induced by paclitaxel inhibits hepatocellular carcinoma cell proliferation though targeting FOXM1.
Huang X; Qin J; Lu S
Int J Clin Exp Pathol; 2015; 8(2):1515-24. PubMed ID: 25973036
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of cFLIP overcomes acquired resistance to sorafenib via reducing ER stress‑related autophagy in hepatocellular carcinoma.
Liu D; Fan Y; Li J; Cheng B; Lin W; Li X; Du J; Ling C
Oncol Rep; 2018 Oct; 40(4):2206-2214. PubMed ID: 30066934
[TBL] [Abstract][Full Text] [Related]
40. Activator of thyroid and retinoid receptor increases sorafenib resistance in hepatocellular carcinoma by facilitating the Warburg effect.
Ma L; Liu W; Xu A; Ji Q; Ma Y; Tai Y; Wang Y; Shen C; Liu Y; Wang T; Han J; Zhao C
Cancer Sci; 2020 Jun; 111(6):2028-2040. PubMed ID: 32279388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]